Low Density Lipoprotein Receptor (LDLR) and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (HMGCR) Expression are Associated with Platinum-Resistance and Prognosis in Ovarian Carcinoma Patients

References

• Stanojevic Z, Djordjevic B, Pajovic SB, Zivanov-Curlis J, Najman S. Molecular pathogenesis of borderline and invasive ovarian tumors. J Buon. 2009;14(1):7–18.19373941
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–516. doi:10.1038/nrc112312835670
   PubMed Web of Science ®Google Scholar
• Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389–393. doi:10.1200/JCO.1991.9.3.3891999708
   PubMed Web of Science ®Google Scholar
• Zhou F, Yang X, Zhao H, et al. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8(19):5200–5212. doi:10.7150/thno.2780630555541
   PubMed Web of Science ®Google Scholar
• Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, Phase 3, randomised controlled trial. Lancet Oncol. 2018;19(8):1117–1125. doi:10.1016/S1470-2045(18)30333-430026000
   PubMed Web of Science ®Google Scholar
• Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126–1134. doi:10.1016/S1470-2045(18)30343-730026002
   PubMed Web of Science ®Google Scholar
• Binju M, Padilla MA, Singomat T, et al. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. Biochim Biophys Acta Gen Subj. 2019;1863(2):371–378. doi:10.1016/j.bbagen.2018.11.00530423357
   PubMed Web of Science ®Google Scholar
• Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 2018;38(1):27. doi:10.1186/s40880-018-0301-4
   Web of Science ®Google Scholar
• Sarkar P, Rao BD, Chattopadhyay A. Cell cycle dependent modulation of membrane dipole potential and neurotransmitter receptor activity: role of membrane cholesterol. ACS Chem Neurosci. 2020;11(18):2890–2899. doi:10.1021/acschemneuro.0c0049932786305
   PubMed Web of Science ®Google Scholar
• Dos Santos CR, Domingues G, Matias I, et al. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis. 2014;13:16. doi:10.1186/1476-511X-13-1624428917
   PubMed Web of Science ®Google Scholar
• Revilla G, Pons MP, Baila-Rueda L, et al. Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness. Sci Rep. 2019;9(1):10260. doi:10.1038/s41598-019-46727-231311983
   PubMed Web of Science ®Google Scholar
• He M, Zhang W, Dong Y, et al. Pro-inflammation NF-kappaB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res. 2017;36(1):15. doi:10.1186/s13046-017-0490-828100270
   PubMed Web of Science ®Google Scholar
• Guo D, Reinitz F, Youssef M, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011;1(5):442–456. doi:10.1158/2159-8290.CD-11-010222059152
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95. doi:10.1038/nrc298121258394
   PubMed Web of Science ®Google Scholar
• Ramadan S, Arm J, Silcock J, et al. Lipid and metabolite deregulation in the breast tissue of women carrying BRCA1 and BRCA2 Genetic Mutations. Radiology. 2015;275(3):675–682. doi:10.1148/radiol.1514096725734415
   PubMed Web of Science ®Google Scholar
• Criscuolo D, Avolio R, Calice G, et al. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer. Cells. 2020;9:4. doi:10.3390/cells9040828
   Web of Science ®Google Scholar
• Kim S, Lee M, Dhanasekaran DN, Song YS. Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer. BMC Cancer. 2018;18(1):1232. doi:10.1186/s12885-018-5152-530526541
   PubMed Web of Science ®Google Scholar
• Klein-Szanto AJP, Bassi DE. Keep recycling going: new approaches to reduce LDL-C. Biochem Pharmacol. 2019;164:336–341. doi:10.1016/j.bcp.2019.04.00330953636
   PubMed Web of Science ®Google Scholar
• Chang WC, Wang HC, Cheng WC, et al. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity. Endocr Relat Cancer. 2020;27(2):81–95. doi:10.1530/ERC-19-009531815680
   PubMed Web of Science ®Google Scholar
• Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–755. doi:10.1097/IGC.0b013e31821b256821543936
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.38421892204
   PubMed Web of Science ®Google Scholar
• de Gonzalo-calvo D, Lopez-Vilaro L, Nasarre L, et al. Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. Bmc Cancer;2015. 15. doi:10.1186/s12885-015-1014-625603878
   PubMed Web of Science ®Google Scholar
• Espinosa G, Lopez-Montero I, Monroy F, Langevin D. Shear rheology of lipid monolayers and insights on membrane fluidity. Proc Natl Acad Sci U S A. 2011;108(15):6008–6013. doi:10.1073/pnas.101857210821444777
   PubMed Web of Science ®Google Scholar
• Wu Y, Si R, Tang H, et al. Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma. Biochem Biophys Res Commun. 2015;457(4):614–620. doi:10.1016/j.bbrc.2015.01.03525603057
   PubMed Web of Science ®Google Scholar
• Rivel T, Ramseyer C, Yesylevskyy S. The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin. Sci Rep-Uk. 2019;2:9.
   Google Scholar
• Kopecka J, Trouillas P, Gasparovic AC, Gazzano E, Assaraf YG, Riganti C. Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat. 2020;49:100670. doi:10.1016/j.drup.2019.10067031846838
   PubMed Web of Science ®Google Scholar
• Hsu -H-H, Chen M-C, Baskaran R, et al. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018;233(7):5458–5467. doi:10.1002/jcp.2640629247488
   PubMed Web of Science ®Google Scholar
• Allott EH, Howard LE, Cooperberg MR, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349–2356. doi:10.1158/1055-9965.EPI-14-045825304929
   PubMed Web of Science ®Google Scholar
• Zhang D, Xi Y, Feng Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies. Eur J Cancer Prev. 2021;30(2):161–170. doi:10.1097/CEJ.000000000000059732483012
   PubMed Web of Science ®Google Scholar
• Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol. 2006;22:129–157. doi:10.1146/annurev.cellbio.22.010305.10465616753029
   PubMed Web of Science ®Google Scholar
• Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10(2):109–121. doi:10.1038/nrg248119139765
   PubMed Web of Science ®Google Scholar
• Santosa S, Varady KA, AbuMweis S, Jones PJH. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci. 2007;80(6):505–514. doi:10.1016/j.lfs.2006.10.00617113605
   PubMed Web of Science ®Google Scholar